International Journal of Antimicrobial Agents最新文献

{"title":"Evaluation of sulbactam-durlobactam disk diffusion and broth microdilution methods for Acinetobacter baumannii","authors":"Xiaolan Hong ,&nbsp;Xinying Wang ,&nbsp;Xin Xiang ,&nbsp;Siquan Shen ,&nbsp;Shaobo Zhou ,&nbsp;Xubo Dai ,&nbsp;Fupin Hu ,&nbsp;Yan Guo","doi":"10.1016/j.ijantimicag.2025.107659","DOIUrl":"10.1016/j.ijantimicag.2025.107659","url":null,"abstract":"<div><h3>Objective</h3><div>The broth microdilution method was used as a reference method to evaluate the accuracy of sulbactam-durlobactam disk diffusion method for <em>A. baumannii</em>.</div></div><div><h3>Methods</h3><div>In 2023, 504 nonduplicated <em>A. baumannii</em> isolated from 59 hospitals in China were tested by broth microdilution (M07) and disk diffusion method (M02) (10/10 µg) according to the CLSI M100 Ed34 standard. Categorical agreement (CA), minor error (mE), major error (ME), and very major error (VME) were calculated.</div></div><div><h3>Results</h3><div>By broth microdilution, the susceptibility, intermediate, and resistance proportions of <em>A. baumannii</em> against sulbactam-durlobactam were 98.4% (496/504),1% (5/504), and 0.6% (3/504), respectively. Compared to broth microdilution method, the CA and mE of all <em>A. baumannii</em> isolates detected by the disk diffusion method were 99.6% (502/504) and 0.4% (2/504), respectively, with no ME or VME. For carbapenem-susceptible <em>A. baumannii,</em> the CA of the disk diffusion method was 100% (184/184), with no mE and ME. For carbapenem-resistant <em>A. baumannii</em>, the CA and mE were 99.4% (318/320) and 0.6% (2/320), respectively, with no ME or VME. For difficult-to-treat resistant <em>A. baumannii</em>, the CA and mE were 99.2% (249/251) and 0.8% (2/251), respectively, with no ME or VME. For colistin-resistant <em>A. baumannii</em>, the disk diffusion method showed a CA of 100% (12/12) with no mE, ME, or VME.</div></div><div><h3>Conclusions</h3><div>The disk diffusion method (10/10 µg) accurately detects the susceptibility of <em>A. baumannii</em> to sulbactam-durlobactam. This method is characterised by its simplicity, economy, and ease of result interpretation, making it suitable for use in routine clinical microbiology laboratories.</div></div>","PeriodicalId":13818,"journal":{"name":"International Journal of Antimicrobial Agents","volume":"67 1","pages":"Article 107659"},"PeriodicalIF":4.6,"publicationDate":"2025-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145426698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antibiotic-mediated prophage activation: Mechanisms, consequences, and therapeutic implications","authors":"Damir Gavric,&nbsp;Petar Knezevic","doi":"10.1016/j.ijantimicag.2025.107655","DOIUrl":"10.1016/j.ijantimicag.2025.107655","url":null,"abstract":"<div><h3>Objective</h3><div>Prophages, as an integral part of bacterial genomes, play a pivotal role in regulating host virulence and shaping bacterial evolution. Exposure to antibiotics, particularly those that cause DNA damage, can trigger a shift from lysogeny to the lytic cycle, i.e., initiate prophage induction.</div></div><div><h3>Methods</h3><div>This review compares the effects of various antibiotic classes on prophage induction, with particular emphasis on the associated clinical consequences.</div></div><div><h3>Results</h3><div>This process can lead to undesirable consequences, such as increased toxin production, enhanced transduction frequency, and modulation of host phenotypes and virulence traits. Among the most potent inducers are fluoroquinolones, such as ciprofloxacin, which activate stx-harbouring prophages in enterohemorrhagic <em>Escherichia coli</em> (EHEC), resulting in elevated Shiga toxin production and disease exacerbation. This effect is primarily mediated through activation of the bacterial SOS response, although other mechanisms may also contribute. Similarly, subinhibitory concentrations of certain β-lactams, sulphonamides, nitrofurans, and fosfomycin can induce prophages, although the extent of induction varies depending on the antibiotic concentration, phage type, bacterial strain, and detection methodology. The antibiotics that predominantly suppress or inhibit phage induction are aminoglycosides, some macrolides, and newer generation tetracyclines.</div></div><div><h3>Conclusions</h3><div>Further studies on antibiotic-mediated phage induction, particularly those focusing on elucidating the underlying mechanisms of this phenomenon, are necessary to maximize its beneficial effects and minimize potential adverse outcomes during therapy.</div></div>","PeriodicalId":13818,"journal":{"name":"International Journal of Antimicrobial Agents","volume":"67 1","pages":"Article 107655"},"PeriodicalIF":4.6,"publicationDate":"2025-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145408943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antimicrobial peptide CATH-1 combats Streptococcus suis by targeting serine/threonine kinase","authors":"Yi Lu ,&nbsp;Xiaoying Yu ,&nbsp;Yandi Pan,&nbsp;Hang Yin,&nbsp;Qingqing Yang,&nbsp;Xin Shen,&nbsp;Xuefeng Cao,&nbsp;Zhiwei Li,&nbsp;Lianci Peng,&nbsp;Rendong Fang","doi":"10.1016/j.ijantimicag.2025.107656","DOIUrl":"10.1016/j.ijantimicag.2025.107656","url":null,"abstract":"<div><h3>Objectives</h3><div>With the increased bacterial resistance to conventional antibiotics, there is an urgent need for the development of novel antimicrobial agents. Cathelicidins belonging to the family of cationic host defense peptides (HDPs) are a critical component of the innate immune system with antimicrobial and immunomodulatory activities. Our previous study has shown that CATH-1 exhibits potent bactericidal activity against <em>Streptococcus suis</em> (<em>S. suis</em>), but the underlying mechanism is still unclear.</div></div><div><h3>Purpose</h3><div>This study investigated the effect of CATH-1 on the resistance development and antibacterial mechanisms against <em>S. suis</em>.</div></div><div><h3>Methods</h3><div>Drug resistance induction assays, time-kill curves, and Live/Dead bacterial staining were used in this study. To analyze the potential antibacterial targets of CATH-1, integrated proteomic and metabolomic analysis, scanning and transmission electron microscopy, membrane potential determination, molecular docking, GST affinity-isolation assay, cellular thermal shift assay (CETSA), and drug affinity responsive target stability assays (DARTS) were employed. Furthermore, the crucial role of STK in the antibacterial activity of CATH-1 was validated through both <em>in vitro</em> bactericidal tests and a mouse infection model.</div></div><div><h3>Results</h3><div>CATH-1 did not readily induce resistance in <em>S. suis</em>. Multi-omics analysis revealed that CATH-1 exerts its antibacterial effects by modulating multiple pathways, including those related to the cell membrane, bacterial virulence, and energy metabolism. Mechanistically, CATH-1 exhibits dual antibacterial actions by disrupting bacterial membrane integrity and targeting the STK pathway to inhibit capsular polysaccharide (CPS) synthesis. Direct binding between CATH-1 and STK was confirmed by CETSA and DARTS. Crucially, the deletion of the stk gene significantly attenuated the anti-infective efficacy of CATH-1 both <em>in vitro</em> and <em>in vivo</em>.</div></div><div><h3>Conclusion</h3><div>This study reveals a novel dual anti-bacterial mechanism of action of CATH-1, inclduing membrane disruption and inhibition of STK-mediated CPS synthesis, and identifies STK as its key functional target. These findings provide a crucial theoretical foundation and new directions for developing novel anti-infective strategies based on antimicrobial peptides.</div></div>","PeriodicalId":13818,"journal":{"name":"International Journal of Antimicrobial Agents","volume":"67 1","pages":"Article 107656"},"PeriodicalIF":4.6,"publicationDate":"2025-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145400656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Helicobacter pylori eradication enters the adjunctive era: Insights from global clinical trials","authors":"Yang Liu ,&nbsp;Chunyan He ,&nbsp;Yilong Liu ,&nbsp;Chan Lu ,&nbsp;Jingwei Shi","doi":"10.1016/j.ijantimicag.2025.107653","DOIUrl":"10.1016/j.ijantimicag.2025.107653","url":null,"abstract":"","PeriodicalId":13818,"journal":{"name":"International Journal of Antimicrobial Agents","volume":"66 6","pages":"Article 107653"},"PeriodicalIF":4.6,"publicationDate":"2025-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145400697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The antiarrhythmic drugs dronedarone and amiodarone exhibit potent in vitro and in vivo activity against Clostridioides difficile","authors":"Ahmed A. Abouelkhair ,&nbsp;Nader S. Abutaleb ,&nbsp;Mohamed N. Seleem","doi":"10.1016/j.ijantimicag.2025.107649","DOIUrl":"10.1016/j.ijantimicag.2025.107649","url":null,"abstract":"<div><div><em>Clostridioides difficile</em> (<em>C. difficile</em>) is the most prevalent cause of healthcare-associated diarrhea. The limited number of FDA-approved antibiotics for <em>C. difficile</em> infection (CDI), along with increasing rates of treatment failure and recurrence, highlight the critical need for new therapeutic options. Here, we report the anti-<em>C. difficile</em> activity of the antiarrhythmic drugs, dronedarone (DRO) and amiodarone (AMD). Both drugs demonstrated strong efficacy against a panel of 25 clinical isolates of <em>C. difficile</em>, with MIC₅₀ values of 4 µg/mL for DRO and 8 µg/mL for AMD. In a time-kill assay, DRO outperformed the approved drugs, vancomycin (VAN) and fidaxomicin (FDX), reducing the high bacterial inoculum below the limit of detection within 2 h. Additionally, both drugs were more effective than VAN at preventing the formation and germination of <em>C. difficile</em> spores. Mechanistic studies indicated that these drugs exert their effects by disrupting the bacterial cell membrane. Furthermore, in the <em>C. difficile</em> recurrence mouse model, both drugs showed a preventive effect comparable to that of VAN. Our findings suggest that these antiarrhythmic drugs have potential as compelling lead molecule for CDI drug discovery, warranting further investigation and potentially paving the way for new anti-<em>C. difficile</em> therapies.</div></div>","PeriodicalId":13818,"journal":{"name":"International Journal of Antimicrobial Agents","volume":"67 1","pages":"Article 107649"},"PeriodicalIF":4.6,"publicationDate":"2025-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145400709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of ceftazidime-avibactam with other appropriate antimicrobial therapy for the treatment of OXA-48- or KPC-producing Enterobacterales infections in Türkiye: A multi-centre retrospective matched-cohort study","authors":"Abdullah Tarık Aslan ,&nbsp;Elif Seren Tanriverdi ,&nbsp;Sibel Yıldız Kaya ,&nbsp;Gozde Dalgan ,&nbsp;Neşe Saltoğlu ,&nbsp;Ezgi Yılmaz ,&nbsp;Yeliz Çiçek ,&nbsp;Mesut Yılmaz ,&nbsp;Çiğdem Erol ,&nbsp;Özlem Kurt Azap ,&nbsp;Gülşen Hazırolan ,&nbsp;Osman Dağ ,&nbsp;Zeynep Türe Yüce ,&nbsp;Pinar Sagiroglu ,&nbsp;Damla Boztaş ,&nbsp;Muhammed Cihan Işık ,&nbsp;Bariş Otlu ,&nbsp;Patrick N.A. Harris ,&nbsp;David L. Paterson ,&nbsp;Murat Akova","doi":"10.1016/j.ijantimicag.2025.107650","DOIUrl":"10.1016/j.ijantimicag.2025.107650","url":null,"abstract":"<div><h3>Objective</h3><div>Due to underrepresentation of carbapenemase-producing <em>Enterobacterales</em> infections in randomized controlled trials with ceftazidime-avibactam (CZA) and high cost of CZA therapy, other appropriate antimicrobial therapies (OAAT) are still being used for OXA-48- or KPC-producing <em>Enterobacterales</em> infections in Türkiye.</div></div><div><h3>Methods</h3><div>We conducted a multicentre retrospective 1:1 matched cohort study of patients who received ≥48 h of CZA or OAAT for documented OXA-48- or KPC-producing <em>Enterobacterales</em> infections. Patients were matched based on (1) the number of days (± 1 d) from the infection onset to the initiation of therapy, (2) INCREMENT-CPE score (± 1), (3) source of infection, (4) year of infectious episode, and (5) type of causative microorganism.</div></div><div><h3>Results</h3><div>From 5 Turkish university hospitals, 180 patients were enrolled. Baseline characteristics were all similar between treatment groups. At the time of treatment initiation, 63.9% of patients were in the intensive care unit, 35.6% had septic shock and 41.1% required mechanical ventilation support. Thirty-day mortality occurred in 35.6% (32/90) of patients treated with CZA and in 56.7% (51/90) of those receiving OAAT regimens (<em>P</em> = 0.004). Twenty-one-day clinical response was seen in 50% (45/90) and 26.7% (24/90) of patients receiving CZA and OAAT, respectively (<em>P</em> = 0.002). In multivariable logistic regression analyses, CZA treatment was associated with less likelihood of mortality (aOR = 0.37; 95% CI: 0.19–0.71; <em>P</em> = 0.003) and higher likelihood of 21-d clinical response (aOR = 3.32; 95% CI: 1.68–6.53; <em>P</em> &lt; 0·001).</div></div><div><h3>Conclusions</h3><div>Treatment with CZA is associated with more favourable clinical outcomes in treatment of OXA-48- or KPC-producing <em>Enterobacterales</em> infections. A randomized controlled trial is needed to confirm these results.</div></div>","PeriodicalId":13818,"journal":{"name":"International Journal of Antimicrobial Agents","volume":"67 1","pages":"Article 107650"},"PeriodicalIF":4.6,"publicationDate":"2025-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145400641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the susceptome of methicillin-resistant Staphylococcus aureus to oxacillin and cefazolin using integrated transposon-directed insertion site sequencing and proteomics","authors":"Nader Abdelmalek ,&nbsp;Sally W. Yousief ,&nbsp;Alessandro Tanca ,&nbsp;Martin S. Bojer ,&nbsp;Mosaed Saleh A. Alobaidallah ,&nbsp;John E. Olsen ,&nbsp;Bianca Paglietti","doi":"10.1016/j.ijantimicag.2025.107652","DOIUrl":"10.1016/j.ijantimicag.2025.107652","url":null,"abstract":"<div><h3>Objective</h3><div>Methicillin-resistant <em>Staphylococcus aureus</em> (MRSA) poses a significant challenge to public health due to its evolving resistance to antibiotics. This study aimed to identfy the determinants that modulate MRSA susceptibility to β-lactam antibiotics.</div></div><div><h3>Methods</h3><div>An integrated approach combining transposon-directed insertion site sequencing (TraDIS) and proteomics was applied. TraDIS was used to identify genetic determinants influencing susceptibility to oxacillin and cefazolin while proteomics was applied to characterise the adaptive response under sub-inhibitory antibiotic concentrations.</div></div><div><h3>Results</h3><div>Proteomic analysis revealed significant shifts in the protein spectrum under sub-inhibitory concentrations of oxacillin and cefazolin, characterised by stringent response. This included upregulation of amino acid metabolism and oligopeptide transport pathways, and downregulation of arginine biosynthesis. Concurrently, TraDIS screening identified 50 genes whose inactivation conferred a fitness advantage in the presence of both β-lactams, implicating processes such as nucleotide second messenger signalling, DNA repair, and histidine transport. Validation with selected mutants (<em>relA</em>::Tn, <em>mutY</em>::Tn, <em>nsaR</em>::Tn, <em>aroC</em>::Tn, <em>SAUSA300_0432</em>::Tn, <em>SAUSA300_0846</em>::Tn, <em>SAUSA300_0595</em>::Tn) confirmed the improved fitness in the presence of β-lactams. Integrative analysis of proteomic and TraDIS datasets highlighted the implication of the stringent response in mediating MRSA adaptation to oxacillin and cefazolin.</div></div><div><h3>Conclusions</h3><div>These findings establish the 'susceptome' concept, a collection of genes that maintain or potentiate the vulnerability of MRSA strains to β-lactams, providing new targets for therapeutic intervention and strategies to counteract resistance evolution.</div></div>","PeriodicalId":13818,"journal":{"name":"International Journal of Antimicrobial Agents","volume":"66 6","pages":"Article 107652"},"PeriodicalIF":4.6,"publicationDate":"2025-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145400650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and validation of machine learning models to predict vancomycin- and teicoplanin-associated acute kidney injury: A retrospective, multicenter study","authors":"Pin-Yi Lo ,&nbsp;Fan-Ying Chan ,&nbsp;Yi-En Ku ,&nbsp;San-Yuan Wang ,&nbsp;Hsiang-Yin Chen","doi":"10.1016/j.ijantimicag.2025.107651","DOIUrl":"10.1016/j.ijantimicag.2025.107651","url":null,"abstract":"<div><h3>Objective</h3><div>Despite the effectiveness of vancomycin and teicoplanin in managing Gram-positive infections, their nephrotoxicity may prolong hospitalization, and increase morbidity, mortality, and healthcare costs. This study aimed to develop and validate clinically applicable prognostic machine learning models for predicting vancomycin-associated acute kidney injury (VA-AKI) and teicoplanin-associated AKI (TA-AKI).</div></div><div><h3>Methods</h3><div>This retrospective study in Taiwan utilized the Taipei Medical University Clinical Research Database. Patients receiving intravenous vancomycin or teicoplanin therapy between February 2010 and December 2020 were included. Features were selected from 198 variables through recursive feature elimination using feature importance (RFECV) and SHapley Additive exPlanations importance (ShapRFECV). Twelve models were constructed using XGBoost and LightGBM. Model performance was assessed by eight evaluation metrics, including the area under the receiver operating characteristic curve (AUROC). The optimal threshold was determined based on the maximum F₁ score, and the SHAP analysis assisted in model interpretation.</div></div><div><h3>Results</h3><div>Among 9342 included patients, 19.70% (1383/7020) of patients in the training set, 18.58% (326/1755) in the internal validation set, and 20.5% (116/567) in the external validation set developed AKI. The XGBoost model, using features selected by ShapRFECV, demonstrated optimal predictive performance in both internal (AUROC 0.798, 95% confidence interval [CI] 0.791–0.804) and external (AUROC 0.779, 95% CI: 0.767–0.791) validation.</div></div><div><h3>Conclusions</h3><div>The XGBoost model, leveraging time-series data, accurately predicts AKI in vancomycin and teicoplanin users, supporting early risk assessment and personalized patient management. Future multicentre prospective external validation is needed to strengthen its real-world applicability and generalizability.</div></div>","PeriodicalId":13818,"journal":{"name":"International Journal of Antimicrobial Agents","volume":"67 1","pages":"Article 107651"},"PeriodicalIF":4.6,"publicationDate":"2025-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145400702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Membrane-disrupting medium-chain fatty acids reduce Staphylococcus aureus persister cell survival during antibiotic treatment","authors":"Yena Seo ,&nbsp;Minjun Kim ,&nbsp;Dae-Youn Kim ,&nbsp;Ji-Won Park ,&nbsp;Hyun Jung Kim ,&nbsp;Kyun Heo ,&nbsp;Tae-Jong Kim","doi":"10.1016/j.ijantimicag.2025.107648","DOIUrl":"10.1016/j.ijantimicag.2025.107648","url":null,"abstract":"<div><h3>Objective</h3><div>Eliminating persister cells is essential to improve treatment of chronic infections and to limit the emergence of resistant strains. Medium-chain fatty acids (MCFAs) are widely used in cosmetics and antibiotic ointments where <em>Staphylococcus aureus</em> is a common commensal. This study evaluated the potential of MCFAs to eradicate <em>S. aureus</em> persister cells and investigated their mechanisms of action.</div></div><div><h3>Methods</h3><div>The bactericidal activity of MCFAs against <em>S. aureus</em> persisters was assessed after treatment with three antibiotics – ciprofloxacin, oxacillin, and tobramycin. Membrane permeability was analysed by fluorescence microscopy and ATP leakage assays.</div></div><div><h3>Results</h3><div>Octanoic, decanoic, and lauric acids at 10, 1, and 0.1 mM, respectively, significantly reduced antibiotic-surviving cells in persister-enriched populations, independent of antibiotic class. In contrast, myristic acid did not eliminate persisters up to 10 mM, although it was active against exponentially growing cells. The bactericidal activity of MCFAs increased with chain length from octanoic to lauric acid. Killing correlated with enhanced membrane permeability, whereas changes in membrane fluidity or transmembrane potential were not predictive.</div></div><div><h3>Conclusions</h3><div>MCFAs, particularly lauric acid at low concentrations, effectively eradicate <em>S. aureus</em> persisters and may enhance skin health when incorporated into topical products. Their activity increases with chain length and is linked to membrane permeability disruption. Myristic acid, while effective against metabolically active cells, is ineffective against persisters, highlighting physiological differences between growth states.</div></div>","PeriodicalId":13818,"journal":{"name":"International Journal of Antimicrobial Agents","volume":"66 6","pages":"Article 107648"},"PeriodicalIF":4.6,"publicationDate":"2025-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145367917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"One Health: Virtual Special Issue in the International Journal of Antimicrobial Agents","authors":"Reema Singh ,&nbsp;Yonghong Xiao","doi":"10.1016/j.ijantimicag.2025.107645","DOIUrl":"10.1016/j.ijantimicag.2025.107645","url":null,"abstract":"","PeriodicalId":13818,"journal":{"name":"International Journal of Antimicrobial Agents","volume":"66 6","pages":"Article 107645"},"PeriodicalIF":4.6,"publicationDate":"2025-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145336750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}